ACRV
Acrivon Therapeutics, Inc.
Key Financials
Operating Income
$-84114000
↑ 5.7%
Net Income
$-77905000
↑ 3.3%
Shareholders' Equity
$112.5M
↓ 36.4%
Total Assets
$129.7M
↓ 34.0%
Total Liabilities
$17.2M
↓ 13.1%
Cash & Equivalents
$41.5M
↑ 4.2%
EPS (Diluted)
$-2.02
↑ 15.1%
Operating Cash Flow
$-63665000.00
↑ 3.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D/A | 3/23/2026 | View on SEC |
| S-8 | 3/19/2026 | View on SEC |
| 8-K | 3/19/2026 | View on SEC |
| 10-K | 3/19/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ACRV |
| Company Name | Acrivon Therapeutics, Inc. |
| CIK | 1781174 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 617-207-8979 |